Itraconazole as 'bridge therapy' to anti-IgE in a patient with severe asthma with fungal sensitisation. by Pizzimenti, S et al.
CASE REPORT
Itraconazole as ‘bridge therapy’ to anti-IgE in a
patient with severe asthma with fungal sensitisation
Stefano Pizzimenti, Claudia Bussolino, Iuliana Badiu, Giovanni Rolla
Department of Allergy and
Clinical Immunology, University
of Torino & AO Ordine
Mauriziano, Torino, Italy
Correspondence to
Professor Giovanni Rolla,
grolla@mauriziano.it
To cite: Pizzimenti S,
Bussolino C, Badiu I, et al.
BMJ Case Rep Published
online: [please include Day
Month Year] doi:10.1136/
bcr-2012-008462
SUMMARY
Sensitisation to fungi has been reported to play an
important role in a particular phenotype of severe
asthma, the so-called severe asthma with fungal
sensitisation, characterised by high levels of total IgE,
which may be an obstacle to anti-IgE therapy. We
describe here the case of a polysensitised woman with
refractory asthma, sensitised to Aspergillus fumigatus
with high total IgE values (1793 kUA/l), but without the
diagnostic criteria for allergic bronchopulmonary
aspergillosis. Additional therapy with itraconazole leads
to the decrease of total IgE to the limits recommended
for proper omalizumab dosing (30–1500 kUA/l).
Itraconazole, used as bridge therapy, provided us the
opportunity to start anti-IgE treatment in a patient with
high levels of total IgE, beyond the upper limits
recommended for proper prescription of omalizumab.
INTRODUCTION
In patients with severe persistent allergic asthma,
omalizumab has been shown to improve the quality
of life by reducing asthma exacerbation and emer-
gency visit rates.1 Total IgE values are requested to
be in the limits range from 30 to 1500 kUA/l in
order to properly prescribe the drug. A few studies
reported favourable effects of antifungal therapy in
improving the quality of life of asthmatic patients
with fungal sensitisation, in whom a significant
decrease of total IgE has also been observed.
CASE PRESENTATION
A 59-year-old woman with uncontrolled severe
asthma and frequent exacerbations, requiring
courses of oral steroids, while on therapy with
salmeterol/high-dose inhaled fluticasone and
montelukast was evaluated for possible allergic
bronchopulmonary aspergillosis (ABPA). She was
sensitised to Aspergillus fumigatus, house dust
mites and grass pollen.
INVESTIGATIONS
Serum total IgE level, measured during the off-
pollen season, was 1793 kUA/l, with specific grass,
house dust mites, Dermatophagoides pteronyssinus
and A fumigatus IgE, respectively, of 15.3, 8.4 and
11.3 kUA/l. No peripheral eosinophilia was found
and Aspergillus precipitins were absent.
Lung high-resolution CT did not show bronch-
iectases or lung infiltrates. Pulmonary function tests
showed moderate obstruction: forced expiratory
volume in 1 s/vital capacity (FEV1/VC) 57%, with
FEV1 72% predicted. The concentration of frac-
tional exhaled nitric oxide (FENO) was very high
(102 ppb, normal values <25 ppb) and Asthma
Control Test (ACT) revealed a poor control
(score=9, controlled=25, partially controlled ≥20
and <25).
DIFFERENTIAL DIAGNOSIS
Our patient did not fulfil the diagnostic criteria for
ABPA, while the sensitisation to A fumigatus in the
context of severe asthma with worsened control
was indicative of severe asthma with fungal sensi-
tisation (SAFS).
TREATMENT
The patient started itraconazole therapy (200 mg
twice daily) as an add-on therapy for 12 weeks.
After treatment, a significant decrease of total IgE
(1043 ng/ml) was found with no improvement in
asthma control (ACT changed from 9 to 12). At
that time, omalizumab was started at the recom-
mended doses (300 mg every 2 weeks) and therapy
with salmeterol/high dose inhaled fluticasone and
montelukast was continued.
OUTCOME AND FOLLOW-UP
Table 1 shows the improvement in asthma control
during 16 weeks of observation.
After 4 months of anti-IgE therapy, the patient
did not report any exacerbation and the ACT score
improved from 9 to 23, indicating good asthma
control. The monthly prednisone cumulative dose
decreased through the observation period and the
days without symptoms increased (figure 1). On
the other hand, the respiratory function and FENO
did not change.
DISCUSSION
In patients with SAFS, a disorder closely related to
ABPA, the addition of itraconazole to the maximal
asthma therapy may improve the symptoms and
pulmonary function and decrease the serum IgE
levels.2 Vicencio et al3 described the case of a dra-
matic decrease of total IgE serum levels in a child
with SAFS after 6 months itraconazole therapy;
they also reported a significant improvement in pul-
monary function and asthmatic symptoms.
However, in our patient, the antifungal add-on
treatment did not improve the symptoms and pul-
monary function, while it caused the decrease of
total IgE levels, providing us an opportunity to
start omalizumab at the recommended doses with a
favourable change in asthma control.
We cannot exclude that omalizumab, adminis-
tered alone as an off-label medication, could have
caused the same beneficial effects, even without
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itraconazole. Actually, a recent real-life study confirmed that
omalizumab is very efficacious in patients with uncontrolled
severe asthma, even in the subgroup of patients with IgE levels
>700 IU/ml (upper limits were not indicated).4 In patients with
ABPA and very high IgE levels, omalizumab has been used, in
association with prednisone and itraconazole, both of which
may decrease the total IgE levels, with reduced asthma exacerba-
tions and a systemic steroid burden.5 To date, omalizumab has
not been specifically studied in SAFS. Fungal sensitisation has
been reported to be associated with asthma severity,6 7 and in
particular A fumigatus sensitisation and ABPA have been asso-
ciated with progressive lung function decline.8 Additional
studies are required to fully establish the role of antifungal
therapy in severe asthma. Also, more data are needed to under-
stand the relationship between sensitisation, airway colonisation
and lung function.
Learning points
▸ Fungal sensitisation plays an important role in severe
asthma.
▸ Omalizumab has been shown to improve the quality of life,
reducing asthma exacerbations.
▸ Antifungal therapy, through the decrease of total IgE, may
provide the opportunity to start anti-IgE therapy at the usual
recommended doses in patients with SAFS.
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Figure 1 Improvement in asthma control during 16 weeks anti-IgE
therapy.
Table 1 Clinical data and pulmonary function during anti-IgE
therapy
0 4 weeks 8 weeks 12 weeks 16 weeks
FEV1% predicted 79 78 79 80 80
FEV1/VC (%) 57 55 58 61 60
FENO (ppb) 102 97 101 88 93
Number of
exacerbations/month
2.08 2 1 1 0
Monthly Prednisone
consumed (mg)
210 150 75 75 0
Consecutive days
without symptoms
1.03 3 5 8 12
ACT 9 16 18 22 23
ACT, Asthma Control Test; FENO, fractional exhaled nitric oxide; FEV, forced expiratory
volume in 1 s; VC, vital capacity.
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